{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:23:13Z","timestamp":1789730593997,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ40381"],"award-info":[{"award-number":["2022JJ40381"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ50138"],"award-info":[{"award-number":["2023JJ50138"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373826"],"award-info":[{"award-number":["82373826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.actbio.2025.01.038","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T18:18:04Z","timestamp":1737829084000},"page":"373-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Facile integration of a binary nano-prodrug with \u03b1PD-L1 as a translatable technology for potent immunotherapy of TNBC"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-1011","authenticated-orcid":false,"given":"Zongtao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luanfeng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longtianyang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Yun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-9387","authenticated-orcid":false,"given":"Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.actbio.2025.01.038_bib0001","article-title":"THOC2 and THOC5 regulate stemness and radioresistance in triple-negative breast cancer","volume":"8","author":"Bai","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"issue":"11","key":"10.1016\/j.actbio.2025.01.038_bib0002","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.actbio.2025.01.038_bib0003","article-title":"Optimization of combined chemoradiotherapy and immunotherapy for locally advanced esophageal cancer","volume":"2","author":"Zhang","year":"2024","journal-title":"Innovat. Med."},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/INMD.20230025","article-title":"Anti-angiogenic therapy enhances cancer immunotherapy: mmechanism and clinical application","volume":"2","author":"Li","year":"2024","journal-title":"Interdiscip. Med."},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity."},{"issue":"2","key":"10.1016\/j.actbio.2025.01.038_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.actbio.2025.01.038_bib0007","doi-asserted-by":"crossref","first-page":"13226","DOI":"10.1021\/acsnano.4c02337","article-title":"Triune nanomodulator enables exhausted cytotoxic T lymphocyte rejuvenation for cancer epigenetic immunotherapy","volume":"18","author":"Li","year":"2024","journal-title":"ACS. Nano"},{"issue":"7","key":"10.1016\/j.actbio.2025.01.038_bib0008","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14796694.1.1.7","article-title":"Role of gemcitabine in cancer therapy","volume":"1","author":"Toschi","year":"2005","journal-title":"Future Oncol."},{"key":"10.1016\/j.actbio.2025.01.038_bib0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0011","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12951-024-02918-2","article-title":"Histidine phosphatase-ferroptosis crosstalk modulation for efficient hepatocellular carcinoma treatment","volume":"22","author":"Qin","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2025.01.038_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120043","article-title":"Recent advances and prospects in gemcitabine drug delivery systems","volume":"592","author":"Paroha","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2025.01.038_bib0013","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jconrel.2020.09.035","article-title":"Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: ffour birds with one stone","volume":"328","author":"Zhou","year":"2020","journal-title":"J. Control Rel."},{"issue":"2","key":"10.1016\/j.actbio.2025.01.038_bib0014","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1172\/JCI94586","article-title":"Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression","volume":"128","author":"Hossain","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.actbio.2025.01.038_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202300093","article-title":"Promotion of ICD via nanotechnology","volume":"23","author":"Qin","year":"2023","journal-title":"Macromol. Biosci."},{"issue":"10","key":"10.1016\/j.actbio.2025.01.038_bib0016","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.actbio.2025.01.038_bib0017","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","article-title":"Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy","volume":"16","author":"Sun","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"6","key":"10.1016\/j.actbio.2025.01.038_bib0018","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2011-06-363564","article-title":"IFN-\u03b1 enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing","volume":"119","author":"Spadaro","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.actbio.2025.01.038_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20230171","article-title":"Tumor cell membrane-based vaccines: a potential boost for cancer immunotherapy","volume":"4","author":"Yang","year":"2024","journal-title":"Exploration"},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0020","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1038\/s41467-021-24867-2","article-title":"STING suppresses bone cancer pain via immune and neuronal modulation","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.actbio.2025.01.038_bib0021","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","article-title":"Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy","volume":"14","author":"Shae","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"21","key":"10.1016\/j.actbio.2025.01.038_bib0022","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","article-title":"Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment","volume":"184","author":"Lam","year":"2021","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.actbio.2025.01.038_bib0023","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0024","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J. ImmunOther Cancer"},{"issue":"10","key":"10.1016\/j.actbio.2025.01.038_bib0025","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1172\/JCI125413","article-title":"STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"6506","key":"10.1016\/j.actbio.2025.01.038_bib0026","first-page":"6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science (1979)"},{"issue":"43","key":"10.1016\/j.actbio.2025.01.038_bib0027","doi-asserted-by":"crossref","first-page":"58180","DOI":"10.1021\/acsami.4c09833","article-title":"Mesoporous microneedles enabled localized controllable delivery of stimulator of interferon gene agonist nanoexosomes for FLASH radioimmunotherapy against breast cancer","volume":"16","author":"Chen","year":"2024","journal-title":"ACS. Appl. Mater. Interfaces."},{"key":"10.1016\/j.actbio.2025.01.038_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122745","article-title":"Manganese-coordinated nanoparticle with high drug-loading capacity and synergistic photo-\/immuno-therapy for cancer treatments","volume":"312","author":"Chen","year":"2025","journal-title":"Biomaterials"},{"issue":"20","key":"10.1016\/j.actbio.2025.01.038_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202203264","article-title":"In situ formed ROS-responsive hydrogel with STING Agonist and Gemcitabine to intensify immunotherapy against pancreatic ductal adenocarcinoma","volume":"12","author":"Wang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2025.01.038_bib0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jconrel.2024.04.042","article-title":"Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy","volume":"370","author":"Yang","year":"2024","journal-title":"J. Control Rel."},{"key":"10.1016\/j.actbio.2025.01.038_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2017.03.391","article-title":"Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma","volume":"254","author":"Pei","year":"2017","journal-title":"J. Control Rel."},{"issue":"45","key":"10.1016\/j.actbio.2025.01.038_bib0032","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1126\/sciadv.abc1725","article-title":"Trisulfide bond-mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity","volume":"6","author":"Yang","year":"2020","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.actbio.2025.01.038_bib0033","first-page":"337","article-title":"Small changes in the length of diselenide bond-containing linkages exert great influences on the antitumor activity of docetaxel homodimeric prodrug nanoassemblies","volume":"16","author":"Li","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.actbio.2025.01.038_bib0034","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1021\/acs.jmedchem.2c01924","article-title":"A clinically translatable ternary Platinum(IV) prodrug for synergistically reversing drug resistance","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.actbio.2025.01.038_bib0035","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1021\/acsami.9b16209","article-title":"Self-assembled gemcitabine prodrug nanoparticles show enhanced efficacy against patient-derived pancreatic ductal adenocarcinoma","volume":"12","author":"Wu","year":"2020","journal-title":"ACS. Appl. Mater. Interfaces."},{"issue":"11","key":"10.1016\/j.actbio.2025.01.038_bib0036","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1021\/acs.bioconjchem.6b00503","article-title":"Self-delivery nanoparticles of amphiphilic methotrexate-gemcitabine prodrug for synergistic combination chemotherapy via effect of deoxyribonucleotide pools","volume":"27","author":"Wang","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"9","key":"10.1016\/j.actbio.2025.01.038_bib0037","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1039\/C7BM00382J","article-title":"Gemcitabine-camptothecin conjugates: a hybrid prodrug for controlled drug release and synergistic therapeutics","volume":"5","author":"Hou","year":"2017","journal-title":"Biomater. Sci."},{"issue":"22","key":"10.1016\/j.actbio.2025.01.038_bib0038","doi-asserted-by":"crossref","first-page":"8319","DOI":"10.1021\/jo9911140","article-title":"Selective protection of 2\u2032,2\u2032-difluorodeoxycytidine (Gemcitabine)","volume":"64","author":"Guo Zw","year":"1999","journal-title":"J. Org. Chem."},{"issue":"4","key":"10.1016\/j.actbio.2025.01.038_bib0039","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/pharmaceutics15041131","article-title":"Development of a peptide-based nano-sized cathepsin B inhibitor for anticancer therapy","volume":"15","author":"Park","year":"2023","journal-title":"Pharmaceutics."},{"issue":"10","key":"10.1016\/j.actbio.2025.01.038_bib0040","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.7150\/thno.97768","article-title":"Biomarker-driven molecular imaging probes in radiotherapy","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics."},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202308762","article-title":"Targeting DNA damage and repair machinery via delivering WEE1 inhibitor and platinum (IV) prodrugs to stimulate STING pathway for maximizing chemo-immunotherapy in bladder cancer","volume":"36","author":"Wang","year":"2024","journal-title":"Adv. Mater."},{"issue":"4","key":"10.1016\/j.actbio.2025.01.038_bib0042","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.7150\/thno.45777","article-title":"Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy","volume":"11","author":"Cai","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.actbio.2025.01.038_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120666","article-title":"Cargo-free immunomodulatory nanoparticles combined with anti-PD-1 antibody for treating metastatic breast cancer","volume":"269","author":"Zhang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2025.01.038_bib0044","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jconrel.2022.03.018","article-title":"Multicyclic topology-enhanced anticancer drug delivery","volume":"345","author":"Ma","year":"2022","journal-title":"J. Control Rel."},{"issue":"33","key":"10.1016\/j.actbio.2025.01.038_bib0045","doi-asserted-by":"crossref","first-page":"8430","DOI":"10.1016\/j.biomaterials.2013.07.037","article-title":"Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy","volume":"34","author":"Yang","year":"2013","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.actbio.2025.01.038_bib0046","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1021\/ma102574e","article-title":"Biodegradable multiblock poly[N-(2-hydroxypropyl)methacrylamide] via reversible addition-fragmentation chain transfer polymerization and click chemistry","volume":"44","author":"Luo","year":"2011","journal-title":"Macromolecules."},{"issue":"11","key":"10.1016\/j.actbio.2025.01.038_bib0047","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3390\/molecules23112906","article-title":"Co-delivery of Gemcitabine and Paclitaxel in cRGD-modified long circulating nanoparticles with asymmetric lipid layers for breast cancer treatment","volume":"23","author":"Zhang","year":"2018","journal-title":"Molecules."},{"issue":"4","key":"10.1016\/j.actbio.2025.01.038_bib0048","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.18632\/oncotarget.2948","article-title":"Inhibition of HIF-1\u03b1 by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget."},{"issue":"12","key":"10.1016\/j.actbio.2025.01.038_bib0049","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/2326-6066.CIR-17-0229","article-title":"Natural killer T-cell immunotherapy in combination with chemotherapy-induced immunogenic cell death targets metastatic breast cancer","volume":"5","author":"Gebremeskel","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0051","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1038\/s41467-019-11730-8","article-title":"Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence","volume":"10","author":"Song","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2025.01.038_bib0052","first-page":"187","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.01.038_bib0053","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.actbio.2025.01.038_bib0054","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mattod.2022.11.008","article-title":"Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier","volume":"62","author":"Wan","year":"2023","journal-title":"Mater. Today (Kidlington)"},{"issue":"9","key":"10.1016\/j.actbio.2025.01.038_bib0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS-STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2025.01.038_bib0056","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41392-022-01252-z","article-title":"Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"suppl_12","key":"10.1016\/j.actbio.2025.01.038_bib0057","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx237","article-title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","volume":"28","author":"S\u00e1nchez-Paulete","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.actbio.2025.01.038_bib0058","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"5966","key":"10.1016\/j.actbio.2025.01.038_bib0059","first-page":"656","article-title":"Development of monocytes, macrophages, and dendritic cells","volume":"327","author":"Geissmann","year":"2010","journal-title":"Science (1979)"},{"issue":"4","key":"10.1016\/j.actbio.2025.01.038_bib0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2025.01.038_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105301","article-title":"Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective","volume":"107","author":"Liu","year":"2024","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.actbio.2025.01.038_bib0062","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:59:45Z","timestamp":1778824785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":62,"alternative-id":["S1742706125000467"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.01.038","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Facile integration of a binary nano-prodrug with \u03b1PD-L1 as a translatable technology for potent immunotherapy of TNBC","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}